机构：[1]Department of Ophthalmology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.[2]Department of Orthopedics, The Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.[3]Department of Rheumatology and Immunology, The First People's Hospital of Xuzhou, Xuzhou, 221002, Jiangsu, People's Republic of China. 13685138802@163.com.[4]Department of Dermatology, Xuzhou Municipal Hospital Affiliated With Xuzhou Medical University, Xuzhou, 221002, Jiangsu, People's Republic of China. gzq199207@163.com.[5]Department of Ophthalmology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. jiangyanyun@163.com.
第一作者机构：[1]Department of Ophthalmology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
推荐引用方式(GB/T 7714)：
Luo Liying,Guan Zhiyuan,Jin Xiao,et al.Correction: Identification of kukoamine a as an anti-osteoporosis drug target using network pharmacology and experiment verification[J].MOLECULAR MEDICINE.2023,29(1):doi:10.1186/s10020-023-00654-1.
APA：
Luo Liying,Guan Zhiyuan,Jin Xiao,Guan Zhiqiang&Jiang Yanyun.(2023).Correction: Identification of kukoamine a as an anti-osteoporosis drug target using network pharmacology and experiment verification.MOLECULAR MEDICINE,29,(1)
MLA：
Luo Liying,et al."Correction: Identification of kukoamine a as an anti-osteoporosis drug target using network pharmacology and experiment verification".MOLECULAR MEDICINE 29..1(2023)
